# Comparison of Vasodilator Response of Inhaled Epoprostenol and Inhaled Nitric Oxide

Study · id `cardio:ct-nct04231084` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04231084](<https://clinicaltrials.gov/study/NCT04231084>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04231084

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 115 participants.

## Technical summary

Registry record NCT04231084. Randomized; triple masking; primary purpose diagnostic. Start 2021-01-15 (actual); primary completion 2024-08-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose diagnostic
- Phase: Phase 4
- Enrolled: 115 participants (enrolled count; ClinicalTrials.gov record NCT04231084, source copy `cardio:ctgov-nct04231084-2024-08-06`, retrieved 2026-10-31)
- Started: 2021-01-15 (actual) (ClinicalTrials.gov record NCT04231084, source copy `cardio:ctgov-nct04231084-2024-08-06`, retrieved 2026-10-31)
- Primary completion: 2024-08-01 (actual) (ClinicalTrials.gov record NCT04231084, source copy `cardio:ctgov-nct04231084-2024-08-06`, retrieved 2026-10-31)
- Completion: 2024-08-01 (actual) (ClinicalTrials.gov record NCT04231084, source copy `cardio:ctgov-nct04231084-2024-08-06`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT04231084, source copy `cardio:ctgov-nct04231084-2024-08-06`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04231084-2024-08-06`, retrieved 2026-10-31)

## The registry's words

- Brief title: Comparison of Vasodilator Response of Inhaled Epoprostenol and Inhaled Nitric Oxide
- Condition: Pulmonary Hypertension
- Intervention (Drug): Vasodilator testing (Inhaled Nitric Oxide)
- Intervention (Drug): Vasodilator testing (Inhaled Epoprostenol)
- Lead sponsor: Brigham and Women's Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry lists this organization as the lead sponsor: Brigham and Women's Hospital (`cardio:org-brigham-and-women-s-hospital`)

## Provenance

Content hash: 7946545d6e1da6f65f42fd773a8f0f10aa9a8a7af2778f46aa9f20eb6fb4d1f2
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
